In patients with raised baseline plasma IL-@ / @/@ and/or PTX@ the eGFR decline during the trial was significantly less in those treated with atorvastatin compared to placebo ( mean change , -@ ; vs. + @ mL/min/@ @ m@/year ; difference , @ @ % CI @ - @ ; p = @ ) , whilst those without raised inflammatory biomarkers showed no difference .